{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:48:27Z","timestamp":1777369707442,"version":"3.51.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/fpc.0b013e32835cb2e2","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T10:15:50Z","timestamp":1355825750000},"page":"84-93","source":"Crossref","is-referenced-by-count":44,"title":["Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels"],"prefix":"10.1097","volume":"23","author":[{"given":"Maria","family":"Dobrinas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Crettol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Oneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Lahyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margalida","family":"Rotger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Choong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubin","family":"Lubomirov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin B.","family":"Eap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210213","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF02190738","article-title":"Methadone maintenance treatment: an update.","volume":"245","author":"Bertschy","year":"1995","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R2-6-20210213","doi-asserted-by":"crossref","first-page":"L45","DOI":"10.1016\/0024-3205(94)00937-6","article-title":"The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine.","volume":"56","author":"Kristensen","year":"1995","journal-title":"Life Sci"},{"key":"R3-6-20210213","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0022-3565(25)03418-4","article-title":"Pharmacological comparison of the optical isomers of methadone.","volume":"92","author":"Scott","year":"1948","journal-title":"J Pharmacol Exp Ther"},{"key":"R4-6-20210213","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers.","volume":"81","author":"Eap","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R5-6-20210213","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000167043","article-title":"The effects of chiral isolates of methadone on the cardiac potassium channel IKr.","volume":"113","author":"Lin","year":"2009","journal-title":"Cardiology"},{"key":"R6-6-20210213","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2146\/ajhp070392","article-title":"Methadone-associated Q-T interval prolongation and torsades de pointes.","volume":"66","author":"Stringer","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"R7-6-20210213","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinternmed.2010.26","article-title":"Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval.","volume":"170","author":"Ansermot","year":"2010","journal-title":"Arch Intern Med"},{"key":"R8-6-20210213","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.","volume":"41","author":"Eap","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R9-6-20210213","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"R10-6-20210213","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clpt.2005.08.011","article-title":"Methadone enantiomer plasma levels, CYP2B6, CYP2C19 and CYP2C9 genotypes, and response to treatment.","volume":"78","author":"Crettol","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R11-6-20210213","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","article-title":"ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.","volume":"80","author":"Crettol","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R12-6-20210213","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5414\/CPP45410","article-title":"Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.","volume":"45","author":"Coller","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R13-6-20210213","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/JCP.0b013e3180592ad2","article-title":"Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.","volume":"27","author":"Uehlinger","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R14-6-20210213","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.clpt.2006.09.011","article-title":"ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.","volume":"80","author":"Coller","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R15-6-20210213","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jchromb.2009.03.013","article-title":"Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R, S)-methadone in clinical samples.","volume":"877","author":"Ansermot","year":"2009","journal-title":"J Chromatogr B"},{"key":"R16-6-20210213","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1515\/CCLM.2003.245","article-title":"Automated LC-MS method for the fast stereoselective determination of methadone in plasma.","volume":"41","author":"Souverain","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"R18-6-20210213","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/jpet.104.068973","article-title":"Multiple novel nonsynonymous CYP2B6 gene polymorphisms in caucasians: demonstration of phenotypic null alleles.","volume":"311","author":"Lang","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R21-6-20210213","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.pnpbp.2008.07.009","article-title":"Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment.","volume":"32","author":"Crettol","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R23-6-20210213","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R24-6-20210213","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R25-6-20210213","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","article-title":"Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.","volume":"102","author":"Bray","year":"2010","journal-title":"Br J Cancer"},{"key":"R26-6-20210213","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2125.2008.03321.x","article-title":"Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.","volume":"67","author":"Ekhart","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R27-6-20210213","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516GT Q172H, a marker of CYP2B66, is responsible for decreased expression and activity of CYP2B6 in liver.","volume":"325","author":"Hofmann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R28-6-20210213","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/clpt.2010.127","article-title":"OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths.","volume":"88","author":"Bunten","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R29-6-20210213","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/JCP.0b013e318222b5dd","article-title":"CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer.","volume":"31","author":"Wang","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R31-6-20210213","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/jac\/dkq260","article-title":"Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.","volume":"65","author":"Carr","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R32-6-20210213","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.","volume":"307","author":"Lamba","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R33-6-20210213","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1124\/mol.104.008086","article-title":"A natural CYP2B6 TATA box polymorphism (-82TC) leading to enhanced transcription and relocation of the transcriptional start site.","volume":"67","author":"Zukunft","year":"2005","journal-title":"Mol Pharmacol"},{"key":"R34-6-20210213","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/01213011-200512000-00004","article-title":"Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.","volume":"15","author":"Klein","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R35-6-20210213","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R36-6-20210213","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1086\/522175","article-title":"Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B66 and 26.","volume":"45","author":"Gatanaga","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R37-6-20210213","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00008571-200310000-00005","article-title":"Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0b013e32835cb2e2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T20:35:53Z","timestamp":1745440553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201302000-00006"}},"subtitle":["a CYP2B6 gene resequencing study"],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e32835cb2e2","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}